Trent Wang

May 15, 2024 | nature.com | Trent Wang |Nausheen Ahmed |Andy Chen |Narendranath Epperla |Bradley M. Haverkos |Nasheed M. Hossain | +10 more

AbstractCD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response (CR) prior to infusion. Limited studies have assessed the outcomes of patients infused in CR. A total of 134 patients with LBCL in CR prior to CAR-T infusion were identified from the CIBMTR registry, with median prior lines of therapy of 3 (range 2–9).